ArticleGenome research2012
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients.
Article in Genome research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 183 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
183 citing papers in PubMed, 351 citations in OpenAlex.
- RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.Science translational medicine · 2017Trial
- AmpliconSuite: an end-to-end workflow for analyzing focal amplifications in cancer genomes.Nature methods · 2026Article
- Molecular Basis and Clinical Significance of the High-risk Phenotype of Hepatitis B Virus Genotype C.Journal of clinical and translational hepatology · 2026Review
- Viral persistence and host-state remodeling in virus-associated cancers.Archives of microbiology · 2026Review
- Review
- Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies.Molecular biomedicine · 2026Review
- Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications.Cancer biology & medicine · 2026Review
- The gut-liver-virus axis in hepatitis B and C: microbiota, immunometabolism, and exosome-mediated therapeutic opportunities.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Harnessing viral footprints in circulating free DNA (cfDNA) for early cancer detection: A focus on liquid-biopsy-based screening.International journal of cancer · 2026Review
- Research progress in intratumoral microbiota: unlocking the potential of cancer immunotherapy.Frontiers in immunology · 2026Review
- Review
- Cell cycle pathway alterations predict outcomes post-liver transplantation for hepatocellular carcinoma.Frontiers in transplantation · 2026Article
- Long-read sequencing reveals HBV integration patterns and oncogenic impact on early-onset hepatocellular carcinoma.Genome research · 2025Article
- HCC-derived SNU cell lines as model systems to study HBV life cycle.Journal of virology · 2025Article
- Hepatitis B virus integration and hepatocarcinogenesis.Liver research (Beijing, China) · 2025Review
- Profiles of HBV DNA integration in humans with hepatitis B virus infection: Insights for antiviral treatment.JHEP reports : innovation in hepatology · 2025Article
- Analysis of hepatitis B virus integration identifies KMT2B as a novel cancer-related gene in pancreatic cancer.Clinical and translational medicine · 2025Article
- AVID enables sensitive and accurate viral integration detection across human cancers.Cell reports methods · 2025Article
- Coculture of tumor organoids with pathogenic microorganisms: a novel system to mimicFrontiers in cellular and infection microbiology · 2025Review
- The cancer microbiome.Advances in clinical chemistry · 2025Review
123 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) infection is a leading risk factor for hepatocellular carcinoma (HCC). HBV integration into the host genome has been reported, but its scale, impact and contribution to HCC development is not clear. Here, we sequenced the tumor and nontumor genomes (>80× coverage) and transcriptomes of four HCC patients and identified 255 HBV integration sites. Increased sequencing to 240× coverage revealed a proportionally higher number of integration sites. Clonal expansion of HBV-integrated hepatocytes was found specifically in tumor samples. We observe a diverse collection of genomic perturbations near viral integration sites, including direct gene disruption, viral promoter-driven human transcription, viral-human transcript fusion, and DNA copy number alteration. Thus, we report the most comprehensive characterization of HBV integration in hepatocellular carcinoma patients. Such widespread random viral integration will likely increase carcinogenic opportunities in HBV-infected individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.